Literature DB >> 16884363

Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis.

T Yagyu1, Y Tsuji, S Haruta, T Kitanaka, Y Yamada, R Kawaguchi, S Kanayama, Y Tanase, N Kurita, H Kobayashi.   

Abstract

The purpose of this study was to determine whether Akt and mammalian target of rapamycin (mTOR), downstream targets of phosphatidylinositol 3-kinase, are activated in endometriosis and ovarian cancer specimens. We measured total and phosphorylated levels of Akt and mTOR from 17 frozen ovarian cancers and 15 benign endometriosis specimens (nine from premenopausal women and six from postmenopausal women) by quantitation of signals from western blots using antibodies against these proteins. Elevated phospho-Akt was detected in ovarian cancer versus endometriosis specimens from premenopausal women and endometriosis specimens from postmenopausal women (2.3 +/- 0.45 versus 0.10 +/- 0.06 and 0.17 +/- 0.11; P < 0.05) when the western blot signal of activated kinase was normalized to total kinase levels. Elevated phospho-mTOR was detected in ovarian cancer and postmenopausal endometriosis versus premenopausal endometriosis (0.52 +/- 0.19 and 0.46 +/- 0.29 versus 0.13 +/- 0.08; P < 0.05). Expression of total kinases (normalized to beta-actin) was higher in carcinoma versus endometriosis specimens. Elevation of the active mTOR was specifically detected in postmenopausal endometriosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884363     DOI: 10.1111/j.1525-1438.2006.00625.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  14 in total

1.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

2.  Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study.

Authors:  T Kacan; C Yildiz; S Baloglu Kacan; M Seker; H Ozer; A Cetin
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-01       Impact factor: 2.915

3.  Hypoxia-inducible factor-1α promotes endometrial stromal cells migration and invasion by upregulating autophagy in endometriosis.

Authors:  Hengwei Liu; Zhibing Zhang; Wenqian Xiong; Ling Zhang; Yao Xiong; Na Li; Haitang He; Yu Du; Yi Liu
Journal:  Reproduction       Date:  2017-03-27       Impact factor: 3.906

4.  The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice.

Authors:  Mahaut Leconte; Carole Nicco; Charlotte Ngô; Christiane Chéreau; Sandrine Chouzenoux; Wioleta Marut; Jean Guibourdenche; Sylviane Arkwright; Bernard Weill; Charles Chapron; Bertrand Dousset; Frédéric Batteux
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

Review 5.  Autophagy in endometriosis.

Authors:  Hui-Li Yang; Jie Mei; Kai-Kai Chang; Wen-Jie Zhou; Li-Qing Huang; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Kenjiro Sawada; Masami Hayashi; Masahiko Tsujimoto; Mareo Yamoto; Andres J Klein-Szanto; Russell J Schilder; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Clin Cancer Res       Date:  2009-08-18       Impact factor: 12.531

Review 7.  Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.

Authors:  Masaki Mandai; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

Review 8.  The Multifaceted Role of Autophagy in Endometrium Homeostasis and Disease.

Authors:  Pooja Popli; Ally J Sun; Ramakrishna Kommagani
Journal:  Reprod Sci       Date:  2021-04-20       Impact factor: 2.924

Review 9.  Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?

Authors:  Luciana Cacciottola; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 10.  Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.

Authors:  Seiji Mabuchi; Toru Sugiyama; Tadashi Kimura
Journal:  J Gynecol Oncol       Date:  2016-05       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.